Junn Jacqueline C, Sciubba James J, Bishop Justin A, Zinreich Eva, Tang Mei, Levine Marshall A, Palermo Robert A, Fakhry Carole, Blanco Ray G, Saunders John R, Califano Joseph A, Ha Patrick K
New York Medical College, Valhalla, NY 10595, USA.
Int J Otolaryngol. 2012;2012:508279. doi: 10.1155/2012/508279. Epub 2012 Jul 15.
Background. The purpose of this study was to assess the effects of amifostine on submandibular gland histology in patients receiving chemoradiation therapy. Methods. We conducted a retrospective submandibular gland histologic slide review of HNSCC patients receiving chemoradiation for head and neck squamous cell carcinoma with three different levels of amifostine exposure. We used six scoring parameters: fatty replacement, lobular architecture degeneration, interstitial fibrosis, ductal degeneration, acinar degeneration, and inflammatory component presence. Results. Differences in gender, tumor stage, amifostine dose, age, number of days after neck dissection, and smoking history (pack years) exposure were not significant between the three groups, although there was a difference between groups in the primary subsite (P = 0.006). The nonparametric Cuzick's test for histologic parameters with varied amifostine treatment showed no significance among the three groups. Conclusions. Although patients did not receive a full dose of amifostine due to side effects, varying doses of amifostine had no apparent evident cytoprotective effects in three groups of cancer patients treated with primary chemoradiation.
背景。本研究的目的是评估氨磷汀对接受放化疗的患者下颌下腺组织学的影响。方法。我们对接受头颈部鳞状细胞癌放化疗且氨磷汀暴露水平不同的三组头颈鳞状细胞癌(HNSCC)患者的下颌下腺组织学切片进行了回顾性研究。我们使用了六个评分参数:脂肪替代、小叶结构退变、间质纤维化、导管退变、腺泡退变和炎症成分存在情况。结果。三组之间在性别、肿瘤分期、氨磷汀剂量、年龄、颈清扫术后天数和吸烟史(包年)暴露方面的差异不显著,尽管三组在原发部位存在差异(P = 0.006)。对不同氨磷汀治疗的组织学参数进行的非参数库齐克检验显示三组之间无显著性差异。结论。尽管由于副作用患者未接受全剂量的氨磷汀,但在三组接受原发放化疗的癌症患者中,不同剂量的氨磷汀均未表现出明显的细胞保护作用。